Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreoni

Showing results (1031-1040 of 1,171) with videos related to

Pageof 118
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 3, 2018
Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypesM Falcone, G Tiseo, F Iraci, et al.
Virus Genes|February 24, 2019
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practiceClaudia Alteri, Rossana Scutari, Ada Bertoli, et al.
Antiviral Therapy|September 23, 2017
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practiceMaria Mercedes Santoro, Domenico Di Carlo, Daniele Armenia, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2010
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitorsFrancesca Ceccherini-Silberstein, Kurt Van Baelen, Daniele Armenia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancerFrancesco Graziano, Annamaria Ruzzo, Fotios Loupakis, et al.
Antiviral Research|February 26, 2011
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitroValentina Svicher, Emanuela Balestra, Valeria Cento, et al.
Anticancer Research|July 11, 2006
Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: a phase II studyMaria Cristina Leonardi, Maria Giulia Zampino, Fabrizio Luca, et al.
The American Journal of Gastroenterology|June 20, 2006
Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?Alessia Ciancio, Antonina Smedile, Chiara Giordanino, et al.
The Journal of Antimicrobial Chemotherapy|January 25, 2020
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and ItalyCathia Soulie, Maria Mercedes Santoro, Alexandre Storto, et al.
Ebiomedicine|April 19, 2021
Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patientsEmanuela Balestrieri, Antonella Minutolo, Vita Petrone, et al.
Pageof 118

Showing results (1031-1040 of 1,171) with videos related to

Sort By:
Pageof 118
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 3, 2018
Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypesM Falcone, G Tiseo, F Iraci, et al.
Virus Genes|February 24, 2019
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practiceClaudia Alteri, Rossana Scutari, Ada Bertoli, et al.
Antiviral Therapy|September 23, 2017
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practiceMaria Mercedes Santoro, Domenico Di Carlo, Daniele Armenia, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2010
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitorsFrancesca Ceccherini-Silberstein, Kurt Van Baelen, Daniele Armenia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancerFrancesco Graziano, Annamaria Ruzzo, Fotios Loupakis, et al.
Antiviral Research|February 26, 2011
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitroValentina Svicher, Emanuela Balestra, Valeria Cento, et al.
Anticancer Research|July 11, 2006
Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: a phase II studyMaria Cristina Leonardi, Maria Giulia Zampino, Fabrizio Luca, et al.
The American Journal of Gastroenterology|June 20, 2006
Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?Alessia Ciancio, Antonina Smedile, Chiara Giordanino, et al.
The Journal of Antimicrobial Chemotherapy|January 25, 2020
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and ItalyCathia Soulie, Maria Mercedes Santoro, Alexandre Storto, et al.
Ebiomedicine|April 19, 2021
Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patientsEmanuela Balestrieri, Antonella Minutolo, Vita Petrone, et al.
Pageof 118